Image

2025 UICMEW | January 29, 2025 Pre-Test

UICMEW | Pre-Test Session 3
Name
Name
First
Last
1. Which of the following best describes a limitation of current registrational studies in addressing racial disparities in oncology?
2. Which of the following best explains the mechanism of action of antibody-drug conjugates (ADCs)?
3. Which of the following emerging diagnostics is used for early cancer detection and monitoring of minimal residual disease (MRD)?
4. Which of the following is a key indication for adoptive cell therapy in oncology?
5. Why is addressing health equity important in clinical trials for oncology treatments?

Case:

A 58-year-old African American female presents to the oncology clinic with newly diagnosed metastatic non-small cell lung cancer (NSCLC). Her medical history includes hypertension and type 2 diabetes, both well-controlled. Molecular testing reveals high PD-L1 expression and no actionable mutations. She expresses interest in clinical trial participation but is concerned about the potential risks and whether she would qualify.

6. Which of the following would be the most appropriate next step in managing this patient’s case while addressing health equity and clinical trial participation?